Madrigal Pharmaceuticals (MDGL) Earnings Date & Reports

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality... Show more

Industry: #Pharmaceuticals Other

Get AI intraday signals

A.I. Advisor

published Earnings

MDGL is expected to report earnings to rise 42.44% to -385 cents per share on May 13

Madrigal Pharmaceuticals MDGL Stock Earnings Reports

Q1'25

Est.

$-3.86

Q4'24

Beat

by $1.77

Q3'24

Beat

by $1.84

Q2'24

Beat

by $0.38

Q1'24

Missed

by $1.09

The last earnings report on February 26 showed earnings per share of -271 cents, beating the estimate of -448 cents. With 65.61K shares outstanding, the current market capitalization sits at 7.15B.

View a ticker or compare two or three

Compare

MDGL